Rosetta Genomics Licenses Roche PCR Technology for use in its MicroRNA-Based Diagnostics
News Jan 08, 2008
Rosetta Genomics has announced its wholly owned subsidiary, Rosetta Genomics Inc., has received a license from Roche Molecular Systems to use its PCR technology in Rosetta Genomics' microRNA-based diagnostic tests.
Rosetta Genomics has developed a custom designed, sensitive and specific microRNA detection platform which is based on Roche PCR technology. This proprietary platform allows Rosetta Genomics to identify microRNA biomarkers in several sample types and body fluids, with very high sensitivity and specificity.
"Based on the PCR platform, as well as other proprietary technologies, we are developing a line of highly sensitive microRNA-based products, three of which we expect will launch in 2008," noted Amir Avniel, President and CEO of Rosetta Genomics.
"We have now been granted licenses from both Roche and Nanogen for use of their respective PCR technologies for diagnostic use, and are looking forward to the launch of our first microRNA-based diagnostic tests in 2008".
Neuroblastoma Biomarker Research Advances TreatmentNews
Neuroblastoma, a childhood cancer, is treatable in less than half of aggressive cases, but new RNA biomarkers may help identify high-risk patients faster and lead to better prognosis.READ MORE
The Exercise Regime of the Future Needs to Check Your GenesNews
Forget protein bars - genes may be central to the exercise regimes of the future, as scientists track down gene changes which occur in response to exercise.READ MORE